Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization